Market Expansion:
Customer acquisition is continuing with more than 20 net-new biopharma and CRO customers in 2025, 20 in 2024, and additional wins in 2026, while the platform now supports 19 of the top 50 pharmaceutical companies and CROs. These signals point to expanding penetration across target life-sciences segments.
Innovation-Driven Growth:
The elluminate platform is adding AI agents, automation, and risk-based quality management capabilities. These investments are positioned to attract new customers and deepen engagements with existing clients.
Investor Backing & Capital Strength:
GI Partners’ majority investment in 2024, with Summit Partners retaining a minority stake, was followed by multiple C‑suite appointments in 2026. This combination signals access to capital and organizational build-out for scaling operations and technology.
